#### **Supporting Information**

# Improving glycoproteomic analysis workflow by systematic evaluation of glycopeptide enrichment, quantification, mass spectrometry approach, and data analysis strategies

Zhenyu Sun<sup>1</sup>; T. Mamie Lih <sup>1</sup>; Jongmin Woo<sup>1</sup>; Liyuan Jiao<sup>1</sup>; Yingwei Hu<sup>1</sup>; Yuefan Wang<sup>1</sup>; Hongyi Liu<sup>1</sup>; Hui Zhang<sup>1\*</sup>

<sup>&</sup>lt;sup>1</sup> Department of Pathology, Oncology, Chemical and Biomolecular Engineering, and Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21231

### Contents

Experimental section
SepPak C18 desalting of digested peptides3
TMTpro labeling of peptides
Enrichment of glycopeptides by ZIC-HILIC enrichment 3
Enrichment of glycopeptides by MAX enrichment
Basic reverse phase fractionation 3
LC-MS/MS analysis3
Data analysis 4
Tables
Table S1 HCD collision energy for label-free intact glycopeptides 5
Table S2 HCD collision energy for TMTpro labeled intact glycopeptides 6
Results and discussion
Figure S1 The identification number of salic acid-containing intact glycopeptides from unlabeled and TMTpro labeled intact glycopeptides
Figure S2 Comparative performance of ZIC-HILIC and MAX Enrichment strategies for direct glycopeptide enrichment
Figure S3 The N-glycans of LLNINPNK.T (LAPM1) from different collision energies for mass spectrometry analysis. Numbers in the X-axis represent glycans containing the numbers of Hex (H), HexNAc (N), A (NeuAc), F (fucose), respectively
Figure S4 The characterization of TMT pro labeling intact N- glycopeptides using different collision energies
Figure S5 The number of glycoproteins, glycosites, and N-Glycans identified from different software
Figure S6 Distribution of glycans, peptide backbones, and proteins in TMTprolabeled intact glycopeptides analyzed with different software tools
References

#### **Experimental section**

SepPak C18 desalting of digested peptides. After digestion, samples were centrifugated at  $14000 \times g$  for 15 min, the supernatants containing resulting digested tryptic peptides were desalted with C18 cartridges. Cartridges were conditioned in 1 mL ACN twice and balanced twice each with 1 mL 50% ACN (v/v) 0.1% FA (v/v) and 0.1% TFA (v/v). The samples were loaded and washed in 1 mL 0.1% TFA (v/v) twice, followed by 1 mL 1% FA (v/v). and then elution using 500  $\mu$ L 50% ACN (v/v) 0.1% FA (v/v) twice. The samples were dried in a vacuum centrifuge and stored at -80 °C.

TMTpro labeling of peptides. TMTpro labeling procedure was performed according to the manufacturer's instruction (ThermoFisher). In brief, a total of 300  $\mu$ g peptides were dissolved in 60  $\mu$ L of 100 mM HEPES. TMTpro reagents were dissolved in ACN. A total of 60  $\mu$ L of each TMTpro reagent was added to the corresponding aliquot of peptides. The TMT labeling reaction was incubated at room temperature for 1h with shaking. The reaction was quenched with 5% hydroxylamine at room temperature for 15 min. Then, peptides were desalted using SepPak C18 and subsequently dried by vacuum centrifugation.

Enrichment of glycopeptides by ZIC-HILIC enrichment. Intact glycopeptides were selectively enriched using a ZIC-HILIC micro-column, which was prepared in-house following a previously published protocol literature  $^1$ . Briefly, ZIC-HILIC column was equilibrated in 200  $\mu L$  80% ACN (v/v) 1% TFA (v/v) and repeated for three times. The peptides were loaded into the ZIC-HILIC micro-column, and then the column was washed with 200  $\mu L$  80% ACN (v/v) 1% TFA (v/v) for three times. Enriched glycopeptides were eluted with 200  $\mu L$  0.1% TFA for three times. And subsequently dried by vacuum centrifugation and stored at -80 °C before LC-MS/MS analysis.

Enrichment of glycopeptides by MAX enrichment. To enrich glycopeptides using MAX enrichment, MAX cartridge was sequentially conditioned with 1 mL of methanol twice, 1 mL of ACN twice, 1 mL of 100 mM triethylammonium acetate twice, 1 mL of water twice, and 1 mL of 95% ACN (v/v) 1% TFA (v/v) twice. Samples were dissolved with 1 mL of 95% ACN (v/v) 1% TFA (v/v) and loaded onto cartridge twice  $^{16}$ . The non-glycopeptides were eluted out by 95% ACN (v/v) 1% TFA (v/v) for four times. Finally, intact glycopeptides were eluted by 500  $\mu$ L of 50% ACN (v/v) 0.1% TFA (v/v), dried and stored at -80 °C before LC-MS/MS analysis.

**Basic reverse phase fractionation.** The TMT-labeled samples were reconstituted and loaded onto a 4.6 mm x 250 mm reverse phase (RP) Zorbax 300 A Extend-C18 column with 3.5 μm size beads. Peptides were separated into 24 fractions by following previously established protocol using off-line HPLC fractionation <sup>2</sup>. The fractions were later combined into 12 fractions for LC-MS/MS analysis.

LC-MS/MS analysis. Intact glycopeptides were analyzed by Orbitrap Exploris<sup>TM</sup> 480 MS (Thermo Scientific) combined with Easy-nLC<sup>TM</sup> 1200 system (Thermo Scientific). Samples were reconstituted with 3% ACN in 0.1% formic acid (solvent A) and loaded onto an in-house packed column (75 μm I.D. x 27.5 cm length packed with ReproSil-

Pur 120 C18-AQ, 1.9  $\mu$ m). For label-free intact glycopeptides, loaded peptides were subjected to the gradient with 300  $\mu$ L/min of flow rate as follows: 1 to 4% B (90% ACN 0.1% F.A) for 15 min, 4 to 25% B for 90 min, 25 to 45% B for 20 min, 45 to 90% B for 3 min, isocratic 90% B for 8 min, 90 to 50% B for 2 min, and isocratic 50% B for 5 min. The temperature of the column was maintained by a column heater (Phoenix-ST) at 60°C. The ion source of the mass spectrometer was set up with 1.8 kV of electrospray voltage and 300 °C of ion transfer tube temperature. The precursor ion scan was acquired with 120 K resolution at 200 m/z for from 350 to 2,000 m/z range and AGC value was set as 5 × 10<sup>5</sup>. Precursor ions isolated from 2 m/z width were fragmented by different HCD NCE (**Table S1**) and fragment ions were acquired with 30 K resolution with 1 × 10<sup>5</sup> of AGC value for 64 ms of injection time for a total duty cycle (2 s). The peptide charge state screening was enabled to include 2 to 8 ions with a dynamic exclusion time of 45 s to discriminate against previously analyzed ions between +/- 10 ppm.

For TMTpro labeled intact N-glycopeptides, the gradient as follows: 2 to 6% B (90% ACN 0.1% F.A) for 5 min, 6 to 30% B for 95 min, 30 to 60% B for 25 min, 60 to 90% B for 3 min, isocratic 90% B for 5 min, 90 to 50% B for 2 min, and isocratic 50% B for 5 min. The precursor ion scan was acquired with 60 K resolution at 200 m/z for from 350 to 2000 m/z range. Precursor ions isolated from 0.7 m/z. Fragment ions were acquired with turboTMT. Other parameters are the same as label-free methods.

For the 12 fractionated samples, intact glycopeptides were analyzed by Orbitrap Ascend Tribrid MS (Thermo Scientific) combined with Evosep One system. Samples were reconstituted with 0.1% FA and loaded onto Evotips. Fragment ions were acquired with 30 K resolution with  $3 \times 10^5$  of AGC value for 64 ms of maximum injection time for a total duty cycle (2 s). Other parameters are same as Orbitrap Exploris<sup>TM</sup> 480 MS. Data analysis. The raw data files were analyzed using pGlyco3.0, MS- PyCloud, and MSFragger software <sup>26-28</sup>. For label-free samples, the parameters were set as follows: oxidation [M, +15.995 Da] and acetyl [ProteinN-term, +42.011 Da] for variable modifications. Carbamidomethyl [C, +57.022 Da] for fixed modification, maximum 3 missed cleavages, 10 ppm for precursor tolerance, 20 ppm for fragment tolerance, trypsin for enzyme, and a false discovery rate (FDR) of 1%. The human and mouse protein database were downloaded from UniProt/Swiss-Prot (version, 2019-12). The human N-glycan database in pGlyco 3.0 was used. And for MS- PyCloud, and MSFragger-Glyco search, the same N-glycan database was used. For TMTpro labeled samples, set variable modifications, oxidation [M, +15.995 Da], set fix modifications as follow: carbamidomethyl [C, +57.022 Da], Similar settings were used for TMTpro, except TMTpro [any-N term, + 304.207 Da], and TMTpro [K, + 304.207 Da] were selected as fixed modifications in addition to carbamidomethyl [C, +57.022 Da]. pGlycoQuant software was utilized for quantification <sup>3</sup>.

## **Tables**


Table S1 HCD collision energy for label-free intact glycopeptides

HCD collision energy	Single/Step
20	Single
25	Single
30	Single
35	Single
40	Single
45	Single
55	Single
20_30_40	Step
25_35_45	Step


Table S2 HCD collision energy for TMTpro labeled intact glycopeptides

HCD collision energy	Single/Step
25	Single
30	Single
35	Single
40	Single
45	Single
25_35_45	Step
35_45_55	Step


### Results and discussion




**Figure S1** The identification number of salic acid-containing intact glycopeptides from unlabeled and TMTpro labeled intact glycopeptides.




**Figure S2** Comparative performance of ZIC-HILIC and MAX Enrichment strategies for direct glycopeptide enrichment.




**Figure S3** The N-glycans of LLNINPNK.T (LAPM1) from different collision energies for mass spectrometry analysis. Numbers in the X-axis represent glycans containing the numbers of Hex (H), HexNAc (N), A (NeuAc), F (fucose), respectively.



**Figure S4** The characterization of TMT pro labeling intact N- glycopeptides using different collision energies.



**Figure S5** The number of glycoproteins, glycosites, and N-Glycans identified from different software.



**Figure S6** Distribution of glycans, peptide backbones, and proteins in TMTpro-labeled intact glycopeptides analyzed with different software tools.

### References

- (1) Sun, Z. Y.; Ji, G. H.; Wang, G. L.; Wei, L.; Zhang, Y.; Lu, H. J. One step carboxyl group isotopic labeling for quantitative analysis of intact glycopeptides by mass spectrometry. *Chem. Commun.* **2021**, *57*, 4154-4157. (2) Mertins, P.; Tang, L. C.; Krug, K.; Clark, D. J.; Gritsenko, M. A.; Chen, L. J.; Clauser, K. R.; Clauss, T. R.; Shah, P.; Gillette, M. A.; et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. *Nature Protocols* **2018**, *13*, 1632-1661.
- (3) Kong, S. Y.; Gong, P. Y.; Zeng, W. F.; Jiang, B. Y.; Hou, X. H.; Zhang, Y.; Zhao, H. H.; Liu, M. Q.; Yan, G. Q.; Zhou, X. W.; et al. pGlycoQuant with a deep residual network for quantitative glycoproteomics at intact glycopeptide level. *Nat. Commun.* 2022, *13*,7539.